
Oncology NEWS International
- Oncology NEWS International Vol 15 No 10
- Volume 15
- Issue 10
Pre-IND Meeting for Lovaxin C
xAdvaxis, Inc. has conducted a pre-IND meeting with the FDA regarding its two planned phase II studies for its lead product Lovaxin C, a live Listeria vaccine for the treatment of cervical and head and neck cancers. The IND will be filed once phase I/II studies have been completed. In a separate news release, Advaxis announced that its breast cancer vaccine Lovaxin B, Listeria monocytogenes modified to deliver HER2/neu to immune cells, is in preclinical testing.
NORTH BRUNSWICK, New JerseyAdvaxis, Inc. has conducted a pre-IND meeting with the FDA regarding its two planned phase II studies for its lead product Lovaxin C, a live Listeria vaccine for the treatment of cervical and head and neck cancers. The IND will be filed once phase I/II studies have been completed. In a separate news release, Advaxis announced that its breast cancer vaccine Lovaxin B, Listeria monocytogenes modified to deliver HER2/neu to immune cells, is in preclinical testing.
Articles in this issue
over 19 years ago
Recombinant MAGE-A3 Cancer Immunotherapy Promisingover 19 years ago
WHI Calcium/Vit D Trial:over 19 years ago
Negative Lymph Nodes Predict Survival in Stage III Colon Caover 19 years ago
Oophorectomy Value Varies by BRCA Typeover 19 years ago
FDA Approves Vectibix for Metastatic Colon Caover 19 years ago
Brain Cancer Cells Attract Stem Cells for Angiogenesisover 19 years ago
NCCN Presents Hematologic Ca Congressover 19 years ago
Interim Results for MediGene's Oncolytic Virus NV1020over 19 years ago
GSK Files NDA for Tykerb for Advanced Breast Cancer RxNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.




































